Yacub v. Sandoz Pharmaceuticals Corp.

85 F. Supp. 2d 817, 1999 U.S. Dist. LEXIS 21057, 1999 WL 1485309
CourtDistrict Court, S.D. Ohio
DecidedAugust 20, 1999
DocketC-3-96-297
StatusPublished
Cited by4 cases

This text of 85 F. Supp. 2d 817 (Yacub v. Sandoz Pharmaceuticals Corp.) is published on Counsel Stack Legal Research, covering District Court, S.D. Ohio primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Yacub v. Sandoz Pharmaceuticals Corp., 85 F. Supp. 2d 817, 1999 U.S. Dist. LEXIS 21057, 1999 WL 1485309 (S.D. Ohio 1999).

Opinion

DECISION AND ENTRY OVERRULING PLAINTIFF’S MOTION FOR RECONSIDERATION (DOC. #41); DEFENDANT SANDOZ PHARMACEUTICALS CORPORATION’S MOTION FOR RECONSIDERATION (DOC. #54) OVERRULED; BIFURCATION ORDERED ON ITS MERITS WITH RESPECT TO STATUTE OF LIMITATIONS ISSUE, PLAINTIFF HAVING NOT OPPOSED SAME; CONFERENCE CALL SET

RICE, Chief Judge.

This litigation arises out of the death of Cheryl Yacub on February 17, 1991. The Plaintiff, who is her surviving spouse and the administrator of her estate, brought this action on behalf of the estate and Mariam Yacub, his minor child. The Plaintiff contends that the death of Cheryl Yacub (hereinafter “Cheryl Yacub” or “Ya-cub”) was caused by her taking Parlodel, a drug manufactured by Defendant Sandoz Pharmaceuticals Corporation (“Sandoz”). 1 His Amended Complaint sets forth, in effect, two claims for relief: a survivorship claim on behalf of the estate, and a loss of consortium claim on behalf of Mariam Ya-cub. 2

In a March 27, 1998, Decision and Entry (Doc. # 39), the Court sustained in part and overruled in part a Motion for Summary Judgment (Doc. # 20) filed by San-doz. The Court sustained the Motion to the extent that it sought summary judg *819 ment on the Plaintiffs survivorship claim, which the Court found time-barred by the statute of limitations. The Court overruled the Motion, however, insofar as it sought summary judgment on the loss of consortium claim. The Court also noted that it would file an Expanded Opinion, with reasoning and citation to authority, supporting its decision concerning the survivorship claim.

Upon further reflection, however, the Court reconsidered its ruling and found that the Plaintiffs survivorship claim was not barred by the applicable statute of limitations. As a result, in a December 22, 1998, Decision and Entry (Doc. # 48), the Court vacated its prior Decision and Entry (Doc. #39), insofar as that ruling had granted Sandoz summary judgment on the Plaintiffs survivorship claim. Thereafter, Sandoz filed a Motion for Reconsideration (Doc. #54), directed toward the Court’s December 22, 1998, ruling regarding the statute of limitations and the Plaintiffs survivorship claim. That Motion is pending before the Court for resolution. Also pending before the Court is an October 29, 1998, Motion for Reconsideration (Doc. # 41), filed by the Plaintiff. In that Motion, the Plaintiff seeks reconsideration of the Court’s September 22, 1998, Decision and Entry (Doc. # 40), overruling his “Partial Motion for Summary Judgment” (Doc. # 84). Specifically, the Plaintiff re-raises his previously-rejected argument that collateral estoppel precludes Sandoz from litigating the safety of Parlodel. As a means of analysis, the Court first will address the Plaintiffs Motion for Reconsideration (Doc. #41). The Court then will consider Sandoz’ Motion for Reconsideration (Doc. # 54).

1. Plaintiff’s Motion for Reconsideration (Doc. # hi)

In his Motion for Reconsideration, the Plaintiff challenges the Court’s prior ruling that collateral estoppel does not preclude Sandoz from litigating the issue of Parlodel’s safety as a lactation inhibitor. The Plaintiff previously filed a Motion for Partial Summary Judgment (Doc. # 34) on this issue, arguing that collateral estoppel should apply, based upon a 1994 Food and Drug Administration order which withdrew approval for Parlodel’s use as a physiological lactation inhibitor. In its September 22, 1998, Decision and Entry (Doc. #40), the Court rejected the Plaintiffs collateral estoppel argument for several reasons. ' First the Court noted the absence of “mutuality,” which is a requirement for collateral estoppel under Ohio law. (Id. at 6-8). Second, the Court reasoned that the Plaintiff had failed to establish the elements of collateral estoppel under federal law. 3 In particular, the Court noted that the FDA had essentially entered a default judgment against Sandoz. The Court then recognized that issues resolved by default are not considered to have been “actually litigated” for collateral estoppel purposes. (Id. at 9). Additionally, the Court noted that the precise issues raised in this case had not been raised in the FDA action. Specifically, the Court reasoned: “Plaintiffs state law claims ask the jury to determine whether the Defendant breached ,a duty it owed to Cheryl Yacub ... by marketing Parlodel for the treatment of physiological lactation in February, 1991. The FDA, on the other hand, determined in December, 1994, that the evidence, then available, did not establish that said drug was safe and effective for that use.” (Id.). Finally, the Court found collateral estoppel inapplicable because Sandoz had maintained the burden of proof in the FDA action, whereas the Plaintiff bears the burden of proof in this litigation. (Id.).

Notably, the Plaintiffs Motion for Reconsideration fails to address the Court’s analysis or any pf the foregoing legal conclusions. Rather, in a “Preliminary Statement,” the Plaintiff contends that the Court misconstrued the nature of *820 his prior Motion. In particular, he insists that “[t]he only issue tendered on partial summary judgment ... is that there is no substantial controversy as to the material fact that there is a final adjudication by the FDA regarding withdrawal of the new drug Parlodel....” (Doc. #41 at 3). In his prior Motion, however, the Plaintiff did not seek to have the mere existence of an FDA withdrawal order established. Indeed, the existence of such an order could not be seriously disputed. Rather, the Plaintiff sought to have certain facts conclusively established, through collateral es-toppel, based upon that FDA order. In particular, the Plaintiff relied upon the doctrine of collateral estoppel to prevent Sandoz from litigating the safety of Parlo-del in the present action.

The Court previously rejected the Plaintiffs reliance upon collateral estoppel, however, and his Motion for Reconsideration fails to mention the Court’s detailed substantive analysis of the issue. With the exception of his “Preliminary Statement,” the Plaintiffs Motion for Reconsideration (Doc. # 41) simply repeats, verbatim, the arguments advanced in his earlier Reply Memorandum (Doc. # 37) in support of his failed “Partial Motion for Summary Judgment” (Doc. #34). In short, given the Plaintiffs failure even to address the legal analysis set forth in the Court’s September 22, 1998, Decision and Entry, the Court discerns no meritorious basis upon which to reconsider that ruling. Accordingly, the Plaintiffs Motion for Reconsideration (Doc. 41) is OVERRULED.

II. Defendant’s Motion for Reconsideration (Doc. # 5k)

In its Motion for Reconsideration, San-doz alleges that the Court erred by overruling its prior Motion for Summary Judgment (Doc. #20), insofar as said Motion raised a statute of limitations defense to the Plaintiffs survivorship claim. More specifically, Sandoz asserts that this Court’s December 22, 1998, ruling on the statute of limitations issue “construed the discovery rule for [Ohio Revised Code] § 2305.10 more expansively than any previous Ohio state court judge or federal court interpreting Ohio’s law on the statute of limitations.” (Doc. # 54 at 4).

Free access — add to your briefcase to read the full text and ask questions with AI

Related

United States v. Calderon
243 F.3d 587 (Second Circuit, 2001)

Cite This Page — Counsel Stack

Bluebook (online)
85 F. Supp. 2d 817, 1999 U.S. Dist. LEXIS 21057, 1999 WL 1485309, Counsel Stack Legal Research, https://law.counselstack.com/opinion/yacub-v-sandoz-pharmaceuticals-corp-ohsd-1999.